Efaviranz versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: A prospective study of HIV-positive individuals. HIV-CAUSAL Collaboration.

TitleEfaviranz versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: A prospective study of HIV-positive individuals. HIV-CAUSAL Collaboration.
Publication TypeJournal Article
Year of Publication2016
AuthorsCain L, Caniglia E, Phillips A, Olsen A, Muga R, Pérez-Hoyos S, Abgrall S, Costagliola D, Rubio R, Jarrín I, Bucher H, Fehr J, van Sighem A, Reiss P, Dabis F, Vandenhende M, Logan R, Robins J, Sterne J, Justice A, Tate J, Touloumi G, Paparizos V, Esteve A, Casabona J, Seng R, Meyer L, Jose S, Sabin C and Hernan M
Corporate AuthorsHIV-CAUSAL Collabaration
JournalMedicine (Baltimore)
VolumeOct;95(41):e5133
URLhttps://www.ncbi.nlm.nih.gov/pubmed/27741139
DOI10.1097/MD.0000000000005133